SEC Form 4 · accession 0001237899-15-000045

REGENERON PHARMACEUTICALS, INC. · REGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Robert J Terifay

Officer — SVP Commercial

Period of report

Aug 5, 2015

Accepted (ET)

Aug 7, 2015 · 6:14 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000872589

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Aug 5, 2015	M	3,264	$30.63	A	23,293	D
Common Stock	Aug 5, 2015	M	29,236	$30.63	A	52,529	D
Common Stock	Aug 5, 2015	F	1,521	$588.64	D	51,008	D
Common Stock	Aug 5, 2015	F	14,292	$588.64	D	36,716	D
Common Stock^F1	Aug 6, 2015	S	2,007	$585.22	D	34,709	D
Common Stock^F2	Aug 6, 2015	S	2,482	$587.35	D	32,227	D
Common Stock^F3	Aug 6, 2015	S	2,126	$588.55	D	30,101	D
Common Stock^F4	Aug 6, 2015	S	2,542	$589.76	D	27,559	D
Common Stock^F5	Aug 6, 2015	S	2,486	$590.57	D	25,073	D
Common Stock^F6	Aug 6, 2015	S	957	$591.75	D	24,116	D
Common Stock	Aug 6, 2015	S	23	$592.40	D	24,093	D
Common Stock	Aug 6, 2015	S	800	$593.66	D	23,293	D
Common Stock	holding	—	—		—	1,651	I	By 401(k) Plan

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Incentive Stock Option (right to buy)^F7	$30.63	Aug 5, 2015	M	3,264	D	—	Dec 14, 2020	Common Stock	3,264	0	D
Non-Qualified Stock Option (right to buy)^F7	$30.63	Aug 5, 2015	M	29,236	D	—	Dec 14, 2020	Common Stock	29,236	0	D

Explanation of responses

F1Represents volume-weighted average price of sales of 2,007 shares of Company stock on August 6, 2015 at prices ranging from $584.77 to $585.63. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 6, 2015 at each separate price.
F2Represents volume-weighted average price of sales of 2,482 shares of Company stock on August 6, 2015 at prices ranging from $587.03 to $587.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 6, 2015 at each separate price.
F3Represents volume-weighted average price of sales of 2,126 shares of Company stock on August 6, 2015 at prices ranging from $588.07 to $589.00. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 6, 2015 at each separate price.
F4Represents volume-weighted average price of sales of 2,542 shares of Company stock on August 6, 2015 at prices ranging from $589.12 to $590.11. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 6, 2015 at each separate price.
F5Represents volume-weighted average price of sales of 2,486 shares of Company stock on August 6, 2015 at prices ranging from $590.12 to $591.09. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 6, 2015 at each separate price.
F6Represents volume-weighted average price of sales of 957 shares of Company stock on August 6, 2015 at prices ranging from $591.22 to $592.00. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 6, 2015 at each separate price.
F7The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.